Kennedy, A.M., Frackowiak, R.S., Newman, S.K., Bloomfield, P.M., Seaward, J., Roques, P., Lewington, G., Cunningham, V.J. and Rossor, M.N. (1995) Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer’s disease. Neuroscience Letters, 186, 17-20. doi:10.1016/0304-3940(95)11270-7

has been cited by the following article:

• TITLE: Platelet cytochrome c-oxidase activity in patients with acute schizophrenia in the course of their treatment with risperidone

  AUTHORS: Gulnur Sh. Burbaeva, Irina S. Boksha, Marina S. Turishcheva, Olga K. Savushkina, Alan G. Beniashvili, Georgiy E. Rupchev, Margarita A. Morozova

  KEYWORDS: Schizophrenia; Risperidone; Biochemical Markers; Acute Phase Treatment; Atypical Antipsychotics

  JOURNAL NAME: Health, Vol.3 No.1, January 29, 2011

  ABSTRACT: Objectives: Testing a hypothesis, that platelet cytochrome c-oxidase (COX) activities in patients with paranoid schizophrenia, acute episode, may be linked to dynamics of their clinical patterns and quality of cognitive functioning under antipsychotic treatment. Methods: Psychopatho-logical (PANSS, NSA-16) and cognitive assess-ments; platelet COX enzymatic activity determination, post-hoc nonparametric statistical analysis. Results: Psychopathological and cognitive assessments were done and blood was sampled in patients before (at baseline) and after treatment with risperidone. Following regu- larities were found after the treatment of patients: Significant elevation of COX, wherein the higher was COX at baseline, the more prominent was decrease in PANSSneg and NSA rates; significant negative correlation between COX and executive time in cognitive tests. When the patient group was divided by median of COX at baseline into two subgroups (greater or equal median, and 20% was assigned to the first subgroup; significantly larger amount of patients with PANSSneg by